Skip to content

Research at St Andrews

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

Research output: Contribution to journalEditorial

DOI

Author(s)

Jakko van Ingen, Rob E. Aarnoutse, Peter R. Donald, Andreas H. Diacon, Rodney Dawson, Georgette Plemper van Balen, Stephen H. Gillespie, Martin J. Boeree

School/Research organisations

Abstract

The 600-mg once daily dose of rifampicin plays a key role in tuberculosis treatment. The evidence underpinning this dose is scant. A review of the historical literature identified 3 strands of reasoning. The first is the pharmacokinetic argument: The 600-mg dose yields serum drug concentrations well above the minimum inhibitory concentration of rifampicin against Mycobacterium tuberculosis. The second is the argument that adverse events may be dose related. The third is the economic argument: Rifampicin was prohibitively expensive at the time of its introduction. Recent in vitro, animal, and early bactericidal activity studies suggest that the 600-mg once daily dose is at the lower end of the dose-response curve, refuting the pharmacokinetic argument. The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials.

Close

Details

Original languageEnglish
Pages (from-to)E194-E199
Number of pages6
JournalClinical Infectious Diseases
Volume52
Issue number9
DOIs
Publication statusPublished - 1 May 2011

    Research areas

  • ADVANCED PULMONARY TUBERCULOSIS, ANTITUBERCULOUS ACTIVITY, INITIAL TREATMENT, DOSE RIFAMPIN, HALF-LIFE, CHEMOTHERAPY, RIFAMYCIN, DRUGS, STREPTOMYCIN, MANAGEMENT

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY trial

    Siika, A., McCabe, L., Bwakura-Dangarembizi, M., Kityo, C., Mallewa, J., Berkley, J., Maitland, K., Griffiths, A., Baleeta, K., Mudzingwa, S., Abach, J., Nathoo, K., Thomason, M. J., Prendergast, A. J., Walker, A. S., Gibb, D. M., Mugyenyi, P., Kityo, C., Musiime, V., Wavamunno, P. & 30 othersNambi, E., Ocitti, P., Ndigendawani, M., Kemigisa, M., Acen, J., Olebo, D., Mpamize, G., Amone, A., Okweny, D., Mbonye, A., Nambaziira, F., Rweyora, A., Kangah, M., Kabaswahili, V., Abach, J., Abongomera, G., Omongin, J., Aciro, I., Philliam, A., Arach, B., Ocung, E., Amone, G., Miles, P., Adong, C., Tumsuiime, C., Kidega, P., Otto, B., Apio, F., Baleeta, K. & REALITY Trial Team, 1 Apr 2018, In : Clinical Infectious Diseases. 66, Issue suppl_2, p. S140-S146

    Research output: Contribution to journalArticle

  2. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R., 18 Jun 2018, In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

  3. 2015 epidemic of severe Streptococcus agalactiae sequence type 283 infections in Singapore associated with the consumption of raw freshwater fish: a detailed analysis of clinical, epidemiological, and bacterial sequencing data

    Kalimuddin, S., Chen, S. L., Lim, C. T. K., Koh, T. H., Tan, T. Y., Kam, M., Wong, C. W., Mehershahi, K. S., Chau, M. L., Ng, L. C., Tang, W. Y., Badaruddin, H., Teo, J., Apisarnthanarak, A., Suwantarat, N., Ip, M., Holden, M. T. G., Hsu, L. Y., Barkham, T. & Singapore Group B Streptococcus Consortium, 15 May 2017, In : Clinical Infectious Diseases. 64, suppl_2, p. S145-S152 8 p.

    Research output: Contribution to journalArticle

  4. MRSA transmission dynamics among interconnected acute, intermediate-term, and long-term healthcare facilities in Singapore

    Chow, A., Lim, V. W., Khan, A., Pettigrew, K., Lye, D. C. B., Kanagasabai, K., Phua, K., Krishnan, P., Ang, B., Marimuthu, K., Hon, P-Y., Koh, J., Leong, I., Parkhill, J., Hsu, L-Y. & Holden, M. T. G., 15 May 2017, In : Clinical Infectious Diseases. 64, suppl_2, p. S76-S81 6 p.

    Research output: Contribution to journalArticle

ID: 9672405